Singapore, Oct. 19 -- Nxera Pharma has announced that its subsidiary, Nxera Pharma Japan has entered into an exclusive license, supply and commercialisation agreement with Taiwan-headquartered Synmosa Biopharma Corporation for QUVIVIQ(R) (daridorexant), a treatment for insomnia, in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand.

Under the Agreement, Nxera has granted Synmosa exclusive rights to submit regulatory applications for QUVIVIQ(R), obtain and maintain the applicable regulatory approvals, and commercialise the product in the Territory. Synmosa will lead regulatory affairs, market access, marketing, distribution and sales in each country, while Nxera will be responsible for product su...